ExploRNACap analogsAvantCap AG
Product details
Extinction Coefficient 34 400 M-1 cm-1 at 260nm
Molecular weight (free acid) 1235.79 g/mol
Molecular formula (free acid) C39H49N15O24P4
Salt Na+
Form 100 mM water solution at pH 6.5

AvantCap AG

High yields and capping efficiencies
Enhanced translation

Highlights

  • Proprietary Intellectual Property
  • Additional layer of IP protection
  • Nature-inspired design for improved biological properties
  • Superior translational efficiency in multiple experimental settings (especially in vivo)
  • High-quality of the final mRNA product due to low dsRNA content
  • Possibility of fine-tuning mRNA quality – access to ultrapure mRNA by hydrophobic handle-assisted HPLC purification
  • Ensures high translational activity without the need of RNA body modifications

Read about it the Journal of American Chemical Society

Trinucleotide mRNA Cap Analogue N6-Benzylated at the Site of Posttranscriptional m6Am Mark Facilitates mRNA Purification and Confers Superior Translational Properties In Vitro and In Vivo

J. Am. Chem. Soc. 2024, 146, 12, 8149–8163

 

Broad promoter compatibility

AvantCap® is compatible with plasmid templates containing T7 polymerase φ6.5 promoter both starting with AGG and GGG.

 

AvantCap® produces less dsRNA during in vitro transcription

AvantCap® is compatible with unmodified and modified uridines in vivo: hEPO in C57BL/6 mice

 

mRNA: human EPO | non-modified U or N1-MeΨ | Dose: 1 µg | Caps: Cap 1, AvantCap® | LNP: clinical grade | Administration: intravenous

AvantCap® increases hEPO production up to 2-fold for N1-MeΨ mRNA and up to 6-fold when using natural UTP.